The Innovative Potential™ document: Health Value Economics (HVE), 2022, provides a market- and economic-scaled perspective of The Prospective that is electrochemically activated chemotherapy (EAC) and the chemotherapeutic galvanostat/potentiostat (CGP), please read it.

​​​

The HVE is not a business plan, that shall be found later on this website.

The HVE document makes the macro-scaled financial and economic case for the distribution of the EAC and the CGP technologies and hardwares across the public's health services sectors, essentially answering the questions of:

• How many people are affected; and,

• How many CGP units are required; and,

• At what price points; and,

• What does the rest of the established surgical and pharmaceutical oncology economy look like.

 

The HVE is a case-specific perspective document for the EAC technology. 

​​

​

​​